Contract Pharma Manufacturing News

1. Symbiosis Expands Commercial Capabilities With Addition Of New Stability Chamber 4/1/2026

   Symbiosis Pharmaceutical Services (Symbiosis), a Contract Development and Manufacturing Organisation (CDMO) specialising in the sterile GMP manufacturer of injectable drug products, has expanded its Quality Control (QC) laboratory with the installation of a new 30°C stability chamber.

2. ROIS CDMO Closes On The Acquisition Of US Injectable Manufacturing Facility 4/1/2026

   ROIS, the CDMO arm of ROVI and a leader in injectable manufacturing, today announces closing the acquisition of a state-of-the-art injectable drug product manufacturing and packaging site in Phoenix, Arizona (USA) from Bristol Myers Squibb.

3. Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected For cGMP Manufacturing 4/1/2026

   Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a development and manufacturing agreement with Cytovance Biologics (www.cytovance.com), a leading full-service contract development and manufacturing organization ("CDMO") specializing in mammalian and microbially expressed biologics, to produce cGMP clinical materials for its planned Phase 2 clinical trial of its breast cancer vaccine.

4. Merck Completes Acquisition Of JSR Life Sciences' Chromatography Business, Expanding Protein A Capabilities And Downstream Portfolio 4/1/2026

   Merck, a leading science and technology company, today announced that it has successfully closed the acquisition of the chromatography business of JSR Life Sciences.

5. Samsung Biologics Completes Acquisition Of GSK's Manufacturing Facility In Rockville, Maryland 3/31/2026

   Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company's first manufacturing presence in the United States.

6. Dalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity With RoboFil™ System In Toronto 3/31/2026

   Dalton Pharma Services today announced the successful installation of its RoboFil™ aseptic powder fill-finish system at its Toronto, Canada facility. This fully automated, isolator-based platform expands Dalton's aseptic powder fill-finish capacity and further strengthens the company's position as a market leader.

7. Swiss Rockets Collaborates With Lonza To Advance Torqur's Oncology Drug Candidate Bimiralisib Into Late-Stage Clinical Development 3/31/2026

   Torqur AG, an innovative clinical-stage biotechnology company dedicated to advancing treatments for oncology and dermatology, and Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced a manufacturing agreement for the clinical supply of bimiralisib, an investigational therapy being explored across multiple indications, with its most advanced program in development for the treatment of actinic keratosis (AK).

8. Phio Pharmaceuticals Announces Agreement With U.S. cGMP Manufacturing Source For Drug Product, PH-762 3/30/2026

   Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer.

9. Matricelf Enters Strategic Collaboration With Japan's CiRA Foundation To Advance Next-Generation Regenerative Manufacturing 3/30/2026

   Matricelf Ltd. (TASE: MTLF), a biotechnology company developing a novel autologous engineered neural tissue therapy for patients with spinal cord injury, today announced it has entered into a Collaborative Research Agreement with the CiRA Foundation, a global leader in induced pluripotent stem cell (iPSC) research and regenerative medicine.

10. ImmuneOncia Therapeutics And Lonza Collaborate To Manufacture Danburstotug, A PD-L1 Antibody Targeting Immuno-Oncology 3/30/2026

    ImmuneOncia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on immuno-oncology, and Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced today that the companies signed a manufacturing agreement for late-stage clinical supply of Danburstotug (IMC-001).